Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI vs. experts: can a computer judge speech as well as a human?

NCT ID NCT07347782

Knowledge-focused Sponsor: Pusan National University Yangsan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare how well an AI program (Blings) measures speech clarity in 40 adults with speech disorders from stroke or other neurological conditions. Two speech therapists will also rate the same speech samples. The goal is to see if the AI can reliably replace or assist human judgment. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI software (Blings) for speech analysis
What this could lead to
If successful, this could provide a reliable, automated way to measure speech problems after stroke, helping doctors track recovery more easily.
What could go wrong
This is a small, early-stage study with only 40 participants. The AI may not match human experts in accuracy, and results may not apply to all types of speech disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients aged 18 years or older with neurologic disorders-including amyotrophic lateral sclerosis (ALS), poliomyelitis, cerebellar-related disorders (such as cerebellar atrophy or degeneration and cerebellar lesions), and stroke-who present with concomitant speech disorders, such as dysarthria, motor speech disorders, and voice disorders. Participants must have sufficient cognitive function, defined as a Korean Mini-Mental State Examination (K-MMSE) score of 16 or higher, and must be capable of understanding and following the examiner's instructions. Individuals with visual, perceptual, or auditory impairments that interfere with participation in speech assessment, as well as those deemed unsuitable for study participation by the investigator for other clinical or practical reasons, are excluded.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Patients with neurologic disorders, including amyotrophic lateral sclerosis, poliomyelitis, cerebellar disorders, cerebellar lesions, and stroke. * Patients presenting with concomitant speech disorders, such as dysarthria, motor speech disorders, and voice disorders. Exclusion Criteria: * Subjects with a score of less than 16 points on the Korean Mini-Mental State Examination (K-MMSE). * Subjects with visual, perceptual, or auditory impairments that prevent them from following the examiner's instructions. * Subjects judged by the researcher as unsuitable for participation in this clinical study due to other reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis cerebellar disorder poliomyelitis speech disorder stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Patients with speech disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.